ERBB2 and breast cancer: Multiple previous and present studies on BC support that the immune response is more obvious in the ER‐negative subtype6, 7, 25; therefore, we hypothesize that the immune system may be more influenced by hormone receptor status than HER2 protein overexpression, and it is very likely that the luminal type is not sensitive to immune signals.